Name: 글로벌 시장 동향
SKU: PH4429
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 레스펄스 시장 규모는 2022년 15억 달러에 달했으며, 2030년까지 25억 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 이 시장은 2023년부터 2030년까지 연평균 6.1%의 성장률을 기록할 것으로 예상됩니다.
레스펄스는 천식, 만성 폐쇄성 폐질환(COPD) 및 기타 폐 질환과 같은 호흡기 질환 환자에게 약물을 투여하는 데 자주 사용됩니다. 기관지 확장제, 코르티코스테로이드 및 기도 확장, 염증 감소, 호흡 개선에 도움이 되는 기타 약물이 레스펄스에 포함될 수 있습니다.
레스펄스를 사용하려면 환자는 일반적으로 레스펄스를 네뷸라이저에 연결한 다음 마우스피스나 마스크를 통해 네뷸라이저에서 분사된 미스트를 흡입합니다. 미세한 미스트는 약물이 폐 깊숙이 침투하여 효율적으로 흡수될 수 있도록 합니다.

시장 동향
가정 의료의 중요성 증대
가정 의료의 중요성 증대는 예측 기간 동안 레스펄스 시장 성장을 이끄는 주요 동인입니다. 가정용 휴대용 네뷸라이저는 가정 의료가 세계 의료 산업에서 입지를 다져감에 따라 환자들이 집에서 치료를 받는 데 필수적인 도구 중 하나가 되었습니다. 최근 몇 년 동안 비용이 많이 드는 입원 치료 대신 가정 치료를 선택하는 사람들이 눈에 띄게 증가했습니다.
휴대용 소형 네뷸라이저는 시장에서 널리 판매되고 있으며 환자들이 집에서 사용하기에 가장 편리한 도구로 홍보되고 있습니다. 기능 향상을 목표로 하는 빈번한 제품 개발은 전 세계 네뷸라이저 시장의 채택률을 높일 것으로 예상됩니다.
부데소니드 흡입제 제네릭 출시 증가
부데소니드 흡입제 제네릭 출시 증가는 예측 기간 동안 시장 성장을 이끄는 중요한 동인입니다. 부데소니드는 염증성 장 질환 환자의 증상을 크게 개선할 수 있습니다. 활동성 질환이 있는 환자의 경우 관해를 촉진할 수도 있습니다.

예를 들어, 2022년 3월 15일 미국 식품의약국(FDA)은 천식 또는 만성 폐쇄성 폐질환(COPD) 치료를 위한 제네릭 심비코트(부데소니드 및 포모테롤 푸마르산염 이수화물) 정량 흡입기를 승인했습니다.
질병 전파 위험 및 대체 치료 옵션
호흡기 기기의 감염 전파 안전성에 대한 우려가 제기되어 왔습니다. 분무기 튜브에서 환자의 폐로 감염이 전파될 가능성이나 기기의 비멸균 챔버를 통한 감염 전파 가능성과 같은 요인으로 인해 의료진은 이러한 기기 사용을 권장하는 데 제약을 받습니다.
예를 들어, 2020년 3월 캐나다 의학 협회 저널에 발표된 논문에 따르면, 분무기 치료 중 호흡기 에어로졸을 다량 생성하여 질병 확산 위험을 높이기 때문에 감염 전파 위험이 증가합니다. 이러한 이유로 최근 몇 년 동안 여러 의료기관에서 분무기 대신 정량 흡입기를 사용하고 있습니다.

COVID-19 영향 분석
영국에서 COVID-19 1차 유행 기간 동안 천식 흡입기 처방이 크게 증가했으며, 제조업체들은 특정 흡입기의 재고 부족을 보고했고, 보건사회복지부는 의료진에게 흡입기 과다 처방을 자제할 것을 촉구하는 성명을 발표했습니다.
같은 기간 동안 일차 진료에서 처리된 천식 악화 건수는 상당히 감소했는데, 이는 천식 약물 복용 순응도 향상으로 설명될 수 있습니다. 다른 설명으로는 바이러스 노출 감소와 의료 서비스 이용에 대한 불안감 등이 있습니다.
러시아-우크라이나 전쟁 영향 분석
러시아-우크라이나 분쟁은 낮은 발생률과 주요 업계 참여자의 부재로 인해 전 세계 레스펄스 시장에 영향을 미쳤습니다. 공급망 중단, 의료 인프라 손상, 전력 공급 차질 등의 요인이 레스펄스 시장 성장에 기여했습니다.

세그먼트 분석
전 세계 레스펄스 시장은 약물 유형, 용량 및 효능, 유통 채널 및 지역별로 세분화됩니다.
부데소니드 약물 유형 세그먼트는 예측 기간 동안 레스펄스 시장 점유율의 대부분을 차지할 것으로 예상됩니다.
부데소니드 약물 유형은 예측 기간 동안 전체 레스펄스 시장의 약 39.1%를 차지합니다. 부데소니드는 흡입 시 기도에서 용량 의존적인 항염증 작용을 하는 글루코코르티코스테로이드입니다. 부데소니드 흡입제는 전신 코르티코스테로이드보다 심각한 부작용이 적습니다. 부데소니드의 항염증 작용을 담당하는 구체적인 기전은 알려지지 않았지만, 천식의 전형적인 염증에 특히 효과적인 것으로 밝혀졌습니다.
예를 들어, 영국 최초의 중등도 천식용 이중 복합 흡입제가 의약품 규제 기관의 승인을 받았습니다. 영국 의약품 및 의료기기 규제청(MHRA)은 중등도 천식용 최초의 이중 복합 완화 흡입제를 승인했습니다. 2023년 3월 23일 아스트라제네카가 발표한 성명에 따르면, 이 흡입기는 영국에서 경증 천식을 앓고 있는 약 270만 명의 성인이 사용할 수 있을 것으로 예상됩니다.

성명에 따르면, 부데소니드/포모테롤 200/6은 임상적으로 충족되지 않은 상당한 수요가 있는 경증 천식에 대해 영국에서 허가된 최초이자 유일한 이중 복합 약물이며, 이번 승인은 9,500명 이상의 환자를 대상으로 한 임상 연구 데이터를 기반으로 이루어졌습니다.
지역 분석
북미는 예측 기간 동안 전 세계 레스펄스 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다.
북미 지역은 예측 기간 동안 전 세계 레스펄스 시장에서 약 41.4%의 점유율로 두 번째로 큰 비중을 차지합니다.
예를 들어, 호흡기 질환의 빈도 증가와 FDA 승인은 이 지역 시장 확대를 견인할 것으로 예상됩니다. 예를 들어, 미국 질병통제예방센터(CDC)에 따르면 2021년 18세 이하 천식 아동의 42.7%가 전년도에 한 번 이상의 천식 발작을 경험했습니다. 5세 미만 천식 아동의 경우 52.9%가 발작을 경험했습니다.
이러한 사실에도 불구하고 천식은 치료 가능하지만, 천식을 앓는 어린이의 절반은 천식이 제대로 조절되지 않는 것으로 추정됩니다. 2020년에는 18세 이상 천식 환자의 40.7%가 전년도에 한 번 이상 천식 발작을 경험했다고 보고했습니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Cipla, AstraZeneca, Sandoz International, Bio chemix Healthcare, Lupin, Amanta Healthcare, Lxir Medilabs, Intra Life, Cosmo Pharmaceuticals 및 Lunan Better Pharmaceutical 등이 있습니다.
보고서 구매 이유

• 유형, 유통 채널 및 지역별 글로벌 레스펄스 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위해

• 모든 세그먼트를 포함한 레스펄스 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서

• 모든 주요 제품을 포함하는 제품 매핑 Excel 파일 제공 주요 업체.
글로벌 레스펄스 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.
대상 고객 (2023년)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Respules Market size reached US$ 1.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.5 billion by 2030. The market is expected to exhibit a CAGR of 6.1% during the forecast period 2023-2030.
Respules are often used to provide medicine to patients suffering from respiratory illnesses such as asthma, chronic obstructive pulmonary disease (COPD) and other lung ailments. Bronchodilators, corticosteroids and other medications that assist to open up the airways, reduce inflammation, and enhance breathing may be included within the respule.
To use a respule, the patient normally connects it to the nebulizer and then inhales the nebulizer mist through a mouthpiece or mask. The thin mist permits the drug to penetrate deep into the lungs, where it may be efficiently absorbed.
Market Dynamics
Growing Prominence of Home Healthcare
Growing prominence of home helathcare is the key driver that drives respules market during the forecast period.Home-use, portable nebulizers have become one of the fundamentals aiding patients at home as home healthcare crafts its own position in the global healthcare industry. In recent years, there has been a marked increase in the choice for home treatment over costly hospitalisations.
Portable, small nebulizers are widely available on the market and are marketed as the most convenient tool for patients to use at home. Frequent category developments aimed at improving functionality are likely to boost the rate of adoption in the worldwide nebulizer market.
Increasing Number Of Launches in Generic Version Of Budesonide Inhaler
The increasing number of generic budesonide inhaler releases is a crucial driver for the market to develop throughout the projected period. Budesonide can significantly improve symptoms in persons with inflammatory bowel disease. In those with active illness, it may also promote remission.
For instance,On march 15 2022 the Food and Drug Administration (FDA) recently approved a generic Symbicort (budesonide and formoterol fumarate dihydrate) metered-dose inhaler for the treatment of asthma or chronic obstructive pulmonary disease (COPD).
Risk of Disease Transmission & Availability Of Alternate Treatment Options
Concerns have been raised about the safety profile of breathing devices in terms of infection transfer. Factors such as the possibility of infection transfer from nebulizer tubing to the patient's lungs or infection transmission from the devices' unsterile chambers restrict healthcare providers' recommendations for the usage of these devices.
For instance According to article published on March 2020 in the Canadian Medical Association Journal, the risk of infection transmission increased during nebulizer treatments due to their ability to generate a high volume of respiratory aerosols, which increases the risk of disease spread. As a result of these considerations, several centres have moved from utilising nebulizers to metered dosage inhalers in recent years.
COVID-19 Impact Analysis
During the first wave of COVID-19 in the UK, there was a significant increase in prescriptions for asthma inhalers, with manufacturers reporting that certain inhalers were out of stock and the Department of Health and Social Care issuing a statement urging practitioners not to overprescribe inhalers.
During the same time period, there was a considerable decrease in the number of asthma exacerbations handled in primary care, with one possible explanation being better adherence to asthma medication. Other explanations include decreased virus exposure and apprehension about presenting to healthcare services.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict had a influence on the global respules market due to its low prevalence and lack of important industry participants. Factors such as supply chain interruption, damage to healthcare infrastructure and access to electricity utilities have all contributed to the rise of repulse makret.
Segment Analysis
The global Respules market is segmented based on drug type, dosage & strength, distribution channel and region.
The Budesonide Drug Type Segment is Estimated To Hold A Majority Of The Respules Market Share During The Forecast Period.
The Budesonide Drug type holds about 39.1% of the total respules market in the forecast period.Budesonide is a glucocorticosteroid that has a dose-dependent anti-inflammatory activity in the airways when breathed. Budesonide inhalation has fewer severe side effects than systemic corticosteroids. Although the specific mechanism responsible for budesonide's anti-inflammatory activity is unknown, it has been found to be particularly efficient against the typical inflammation of asthma.
For instance The UK's first dual combination inhaler for moderate asthma has been approved by the medicines regulator. The UK's first dual combination relief inhaler for moderate asthma has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).
According to a statement released by AstraZeneca on March 23, 2023, the inhaler might be used by approximately 2.7 million adults in the UK who live with mild asthma.
Budesonide/formoterol 200/6 is the first and only dual combination medication licenced in the UK for mild asthma, where there is a significant unmet clinical need," according to the statement, adding that the approval was based on data from clinical studies involving over 9,500 patients.
Geographical Analysis
North America is Estimated to Hold the Largest Share of the Global Respules Market During the Forecast Period.
The North America region holds the second largest share of the global Respules market accounting for approximately 41.4% in the forecast period.
For instance The rising frequency of respiratory diseases, as well as FDA approvals, are likely to drive market expansion in this area.For instance, According to the CDC, 42.7% of children aged 18 and under who had asthma had one or more asthma episodes in the previous year in 2021.A total of 52.9% of children under the age of five who had asthma experienced an episode.
Despite the fact that asthma is treatable, it is believed that half of all children with asthma have uncontrolled asthma. In 2020, 40.7% of individuals aged 18 and up with asthma reported one or more asthma episodes in the previous year.
Competitive Landscape
The major global players in the market include Cipla, AstraZeneca, Sandoz International, Bio chemix Healthcare, Lupin, Amanta Healthcare, Lxir Medilabs, Intra Life, Cosmo Pharmaceuticals and Lunan Better Pharmaceutical.
Why Purchase the Report?
• To visualize the global respules market segmentation based on type, distribution channel, and region,as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of respules market-level with all segments.
• PDF report consists of a comprehensiveanalysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Respules Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.
Target Audience 2023
• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Distribution Channel
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Prominence of Home Healthcare
4.1.1.2. Increasing Number Of Launches in Generic Version Of Budesonide Inhaler
4.1.2. Restraints
4.1.2.1. Risk of Disease Transmission & Availability Of Alternate Treatment Options
4.1.3. Opportunity
4.1.3.1. Increasing approvals in the market
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario before COVID-19
6.1.2. Scenario during COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.1.2. Market Attractiveness Index, By Type
8.2. Budesonide
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Pulmicort Respules
8.2.4. Budecort Respule
8.2.5. Budesules Respules
8.3. Albuterol
8.3.1. Levolin Respules
8.3.2. Asthalin Respules
8.4. Ipratropium Bromide
8.4.1. Ipravent Respules
8.5. Salbutamol sulphate and Ipratropium bromide
8.5.1. Duolin LD Respules
9. By Dosage & Strength
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage & Strength
9.1.2. Market Attractiveness Index, By Dosage & Strength
9.2. 0.25 mg/2 mL*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. 0.5 mg/2 mL
9.4. 1mg/2mL
9.5. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacy
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacy
10.4. Online Pharmacy
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage & Strength
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.6.1. The U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage & Strength
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.6.1. Germany
11.3.6.2. The U.K.
11.3.6.3. France
11.3.6.4. Italy
11.3.6.5. Spain
11.3.6.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage & Strength
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.6.1. Brazil
11.4.6.2. Argentina
11.4.6.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage & Strength
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage & Strength
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Cipla
13.1.1. Company Overview
13.1.2. Type Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. AstraZeneca
13.3. Sandoz International
13.4. Biochemix Healthcare Private Limited
13.5. Lupin Limited
13.6. Amanta Healthcare
13.7. LXIR MEDILABS
13.8. Intra Life
13.9. Cosmo Pharmaceuticals
13.10. Lunan Better Pharmaceutical
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Cipla, 4.	Key Developments, AstraZeneca, Sandoz International, Biochemix Healthcare Private Limited, Lupin Limited, Amanta Healthcare, LXIR MEDILABS, Intra Life, Cosmo Pharmaceuticals, Lunan Better Pharmaceutical

표 목록 (Tables)

List of Tables Table 1 Global Respules Market Value, By Drug, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Respules Market Value, By Dosage & Strength, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Respules Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Respules Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Respules Market Value, By Drug, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Respules Market Value, By Drug, 2021-2030 (US$ Million)

Table 7 Global Respules Market Value, By Dosage & Strength, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Respules Market Value, By Dosage & Strength, 2021-2030 (US$ Million)

Table 9 Global Respules Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Respules Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Respules Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Respules Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Respules Market Value, By Drug, 2021-2030 (US$ Million)

Table 14 North America Respules Market Value, By Dosage & Strength, 2021-2030 (US$ Million)

Table 15 North America Respules Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Respules Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Respules Market Value, By Drug, 2021-2030 (US$ Million)

Table 18 South America Respules Market Value, By Dosage & Strength, 2021-2030 (US$ Million)

Table 19 South America Respules Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Respules Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Respules Market Value, By Drug, 2021-2030 (US$ Million)

Table 22 Europe Respules Market Value, By Dosage & Strength, 2021-2030 (US$ Million)

Table 23 Europe Respules Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Respules Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Respules Market Value, By Drug, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Respules Market Value, By Dosage & Strength, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Respules Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Respules Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Respules Market Value, By Drug, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Respules Market Value, By Dosage & Strength, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Respules Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Cipla: Overview

Table 33 Cipla: Product Portfolio

Table 34 Cipla: Key Developments

Table 35 AstraZeneca: Overview

Table 36 AstraZeneca: Product Portfolio

Table 37 AstraZeneca: Key Developments

Table 38 Sandoz International: Overview

Table 39 Sandoz International: Product Portfolio

Table 40 Sandoz International: Key Developments

Table 41 Biochemix Healthcare Private Limited: Overview

Table 42 Biochemix Healthcare Private Limited: Product Portfolio

Table 43 Biochemix Healthcare Private Limited: Key Developments

Table 44 Lupin Limited: Overview

Table 45 Lupin Limited: Product Portfolio

Table 46 Lupin Limited: Key Developments

Table 47 Amanta Healthcare: Overview

Table 48 Amanta Healthcare: Product Portfolio

Table 49 Amanta Healthcare: Key Developments

Table 50 LXIR MEDILABS: Overview

Table 51 LXIR MEDILABS: Product Portfolio

Table 52 LXIR MEDILABS: Key Developments

Table 53 Intra Life: Overview

Table 54 Intra Life: Product Portfolio

Table 55 Intra Life: Key Developments

Table 56 Cosmo Pharmaceuticals: Overview

Table 57 Cosmo Pharmaceuticals: Product Portfolio

Table 58 Cosmo Pharmaceuticals: Key Developments

Table 59 Lunan Better Pharmaceutical: Overview

Table 60 Lunan Better Pharmaceutical: Product Portfolio

Table 61 Lunan Better Pharmaceutical: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Respules Market Value, 2021-2030 (US$ Million)

Figure 2 Global Respules Market Share, By Drug, 2022 & 2030 (%)

Figure 3 Global Respules Market Share, By Dosage & Strength, 2022 & 2030 (%)

Figure 4 Global Respules Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Respules Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Respules Market Y-o-Y Growth, By Drug, 2022-2030 (%)

Figure 7 Budesonide Respules Market Value, 2021-2030 (US$ Million)

Figure 8 Albuterol Respules Market Value, 2021-2030 (US$ Million)

Figure 9 Ipratropium Bromide Respules Market Value, 2021-2030 (US$ Million)

Figure 10 Salbutamol sulphate and Ipratropium bromide Respules Market Value, 2021-2030 (US$ Million)

Figure 11 Global Respules Market Y-o-Y Growth, By Dosage & Strength , 2022-2030 (%)

Figure 12 0.25 mg/2 mL Dosage & Strength in Global Respules Market Value, 2021-2030 (US$ Million)

Figure 13 0.5 mg/2 mL Dosage & Strength in Global Respules Market Value, 2021-2030 (US$ Million)

Figure 14 1mg/2mL Dosage & Strength in Global Respules Market Value, 2021-2030 (US$ Million)

Figure 15 Global Respules Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 16 Hospital Pharmacy Distribution Channel in Global Respules Market Value, 2021-2030 (US$ Million)

Figure 17 Retail Pharmacy Distribution Channel in Global Respules Market Value, 2021-2030 (US$ Million)

Figure 18 Online Pharmacy Distribution Channel in Global Respules Market Value, 2021-2030 (US$ Million)

Figure 19 Others Distribution Channel in Global Respules Market Value, 2021-2030 (US$ Million)

Figure 20 Global Respules Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Respules Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Respules Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Respules Market Value, 2021-2030 (US$ Million)

Figure 24 South America Respules Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Respules Market Value, 2021-2030 (US$ Million)

Figure 26 North America Respules Market Value, 2021-2030 (US$ Million)

Figure 27 North America Respules Market Share, By Drug, 2022 & 2030 (%)

Figure 28 North America Respules Market Share, By Dosage & Strength, 2022 & 2030 (%)

Figure 29 North America Respules Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 30 North America Respules Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Respules Market Value, 2021-2030 (US$ Million)

Figure 32 South America Respules Market Share, By Drug, 2022 & 2030 (%)

Figure 33 South America Respules Market Share, By Dosage & Strength, 2022 & 2030 (%)

Figure 34 South America Respules Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 35 South America Respules Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Respules Market Value, 2021-2030 (US$ Million)

Figure 37 Europe Respules Market Share, By Drug, 2022 & 2030 (%)

Figure 38 Europe Respules Market Share, By Dosage & Strength, 2022 & 2030 (%)

Figure 39 Europe Respules Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 Europe Respules Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Respules Market Value, 2021-2030 (US$ Million)

Figure 42 Asia-Pacific Respules Market Share, By Drug, 2022 & 2030 (%)

Figure 43 Asia-Pacific Respules Market Share, By Dosage & Strength, 2022 & 2030 (%)

Figure 44 Asia-Pacific Respules Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 Asia-Pacific Respules Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Respules Market Value, 2021-2030 (US$ Million)

Figure 47 Middle East & Africa Respules Market Share, By Drug , 2022 & 2030 (%)

Figure 48 Middle East & Africa Respules Market Share, By Dosage & Strength , 2022 & 2030 (%)

Figure 49 Middle East & Africa Respules Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 Cipla: Financials

Figure 51 AstraZeneca: Financials

Figure 52 Sandoz International: Financials

Figure 53 Biochemix Healthcare Private Limited: Financials

Figure 54 Lupin Limited: Financials

Figure 55 Amanta Healthcare: Financials

Figure 56 LXIR MEDILABS: Financials

Figure 57 Intra Life: Financials

Figure 58 Cosmo Pharmaceuticals: Financials

Figure 59 Lunan Better Pharmaceutical: Financials

글로벌 레스펄스 시장 – 2023-2030

Global Respules Market - 2023-2030